Pipeline
Alectos Therapeutics is currently advancing programs against a number of novel, undisclosed targets in the therapeutic areas of oncology and neurological disease. Of these programs, Alectos has partnered with Merck, a global leader in neurological disease, to advance its Alzheimer’s disease program.
